文献速递认知障碍与痴呆神经免疫

维生素D、吸烟、EBV与MS长期认知表现:BENEFIT 11年随访

Vitamin D, smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFIT.
PubMed 文献 · Neurology · 2020-04-16

研究纳入278例临床孤立综合征患者,随访BENEFIT试验11年,分析基线及6、12、24月的25(OH)D、可替宁和抗EBNA-1 IgG对11年时PASAT-3评分和血清NfL的预测作用。结果显示较高维生素D预测更好认知,吸烟预测更差认知,抗EBNA-1抗体无预测作用。

要点

  • 前2年平均25(OH)D每高50 nmol/L,11年PASAT差评分几率降低65%。
  • 吸烟者及重度吸烟者PASAT标准化评分低于非吸烟者(趋势p=0.026)。
  • 基线抗EBNA-1 IgG水平不预测认知表现(趋势p=0.88)。

核心结论

  • 临床发病后较低维生素D和吸烟预测MS患者更差的长期认知功能和神经元完整性。

研究设计与样本

  • BENEFIT临床试验的11年随访(BENEFIT-11),纳入278例临床孤立综合征患者。

主要发现

  • 前2年平均25(OH)D每高50 nmol/L与11年较差PASAT表现几率降低65%相关(95%CI 0.14-0.89)。
  • 吸烟者和重度吸烟者的PASAT标准化评分低于非吸烟者(趋势p=0.026)。
  • 前2年平均25(OH)D每高50 nmol/L与11年NfL低20%相关(95%CI -36%至0%)。
  • 吸烟者11年NfL水平比非吸烟者高20%(95%CI 2%-40%)。
  • 基线抗EBNA-1 IgG水平不预测认知表现(趋势p=0.88),与NfL无关联。

临床怎么用

  • 对MS患者应关注维生素D水平并鼓励戒烟,以可能改善长期认知结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate whether vitamin D, smoking, and anti-Epstein-Barr virus (EBV) antibody concentrations predict long-term cognitive status and neuroaxonal injury in multiple sclerosis (MS). METHODS: This study was conducted among 278 patients with clinically isolated syndrome who participated in the clinical trial BENEFIT (Betaferon/Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment) and completed the 11-year assessment (BENEFIT-11). We measured serum 25-hydroxyvitamin-D (25(OH)D), cotinine (smoking biomarker), and anti-Epstein-Barr virus nuclear antigen 1 (EBNA-1) immunoglobulin G (IgG) at baseline and at months 6, 12, and 24 and examined whether these biomarkers contributed to predict Paced Auditory Serial Addition Test (PASAT)-3 scores and serum neurofilament light chain (NfL) concentrations at 11 years. Linear and logistic regression models were adjusted for sex, baseline age, treatment allocation, steroid treatment, multifocal symptoms, T2 lesions, and body mass index. RESULTS: Higher vitamin D predicted better, whereas smoking predicted worse cognitive performance. A 50-nmol/L higher mean 25(OH)D in the first 2 years was related to 65% lower odds of poorer PASAT performance at year 11 (95% confidence intervals [95% CIs]: 0.14-0.89). Standardized PASAT scores were lower in smokers and heavy smokers than nonsmokers (p trend = 0.026). Baseline anti-EBNA-1 IgG levels did not predict cognitive performance (p trend = 0.88). Associations with NfL concentrations at year 11 corroborated these findings-a 50-nmol/L higher mean 25(OH)D in the first 2 years was associated with 20% lower NfL (95% CI: -36% to 0%), whereas smokers had 20% higher NfL levels than nonsmokers (95% CI: 2%-40%). Anti-EBNA-1 antibodies were not associated with NfL. CONCLUSIONS: Lower vitamin D and smoking after clinical onset predicted worse long-term cognitive function and neuronal integrity in patients with MS.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Cortese M, Munger KL, Martínez-Lapiscina EH, et al. Vitamin D, smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFIT. Neurology. 2020. PMID: 32300060. doi:10.1212/WNL.0000000000009371

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。